ESTRO 2024 - Abstract Book

S2382

Clinical - Urology

ESTRO 2024

DIL PSMA-SUVmax at SBRT conclusion was a median of 5.3 (IQR, 2.0-13.6). Four (25%) patients had complete metabolic resolution. Cumulative CTCAE acute toxicity of grade 1 and grade 2 were 70% (urinary 45%, rectal 25%) and 30% (urinary 25%, rectal 5%), respectively. None of the patients had grade 3 acute adverse effects.

Conclusion:

Combined DIL-PET and DIL-MRI resulted in a union volume significantly larger than the overlap volume for focal boost. Spatially, substantial discordance was noted between DIL-PET and DIL-MRI with a median dice coefficient of 0.59. The median %SUVmax corresponding to DIL-MRI was 50% and showed significant inverse correlation with baseline DIL-SUVmax. Ga68- P SMA PETCT and M R -guided B oost for intra-prostatic dose E scalation (PROBE) was feasible and resulted in cumulative grade 2 acute urinary and rectal toxicity of 25% and 5%, respectively, with no grade 3 acute adverse effects. (The authors acknowledge funding support for this study from Siemens Healthineers, Inc.)

Keywords: Prostate SBRT, Focal Boost, PSMA-PET

1029

Digital Poster

Concomitant Chemotherapy in Trimodal Treatment of Patients with Muscle Invasive Bladder Cancer.

Camille Baudelin 1 , Michael Baboudjian 2 , Derek Dinart 3 , Christophe Hennequin 4 , Nam-Son Vuong 5 , Nicolas Benziane 6 , Diego Teyssonneau 1 , Paul Sargos 6 , Guilhem Roubaud 1 1 Institut Bergonié, Medical Oncology, Bordeaux, France. 2 APHM, Urology, Marseille, France. 3 Institut Bergonié, Clinical Research and Clinical Epidemiology, Bordeaux, France. 4 Hôpital Saint-Louis, Radiation Oncology, Paris, France. 5 Clinique Saint-Augustin, Urology, Bordeaux, France. 6 Institut Bergonié, Radiation Oncology, Bordeaux, France

Purpose/Objective:

Trimodal therapy (TMT), incorporating transurethral resection of the bladder tumor and chemoradiotherapy, is a bladder sparing alternative to radical cystectomy for select patients with muscle- invasive bladder cancer (MIBC). Concurrent chemotherapy (CC) is a pivotal component of TMT, however, due to the lack of randomized controlled trials, the optimal CC protocol remains unknown. This systematic review aims to comprehensively assess CC protocols used during TMT, focusing on efficacy and safety outcomes to guide clinical decisions.

Material/Methods:

A systematic literature search in the PubMed and Embase databases was performed to identify eligible studies performed from 1980 to March 2023. The Preferred Reporting Items for Systematic Reviews and Meta-analyses